Wilkinson ST

Feasibility and tolerability of virtual reality during esketamine treatment: A pilot study.

Curran E, Kumpf KT, Ansari M +4

ArticlePsilocybin

Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.

King A, Hardy M, Rhee TG +1

Combined Ketamine and Cognitive-Behavioral Therapy: Leveraging Metaplasticity to Enhance Treatment Outcomes.

Hardy MS, Li SW, Wilkinson ST

Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search.

Abukahok N, Lawrence S, Adhikari S +2

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial.

Wilkinson ST, Kitay BM, Macaluso M +10

Concurrent SSRI, SNRI, or Other Antidepressant Use Not Associated With Differential Outcomes in Ketamine or Esketamine Treatment.

Curran E, Hardy M, Katz R +2

Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study.

Zaki N, Chen LN, Lane R +7

Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.

Wilkinson ST, Prashad S, Dalthorp R +10

Questionable Data and Design in Esketamine Study.

Wilkinson ST, Rhee TG

Ketamine and Esketamine: Is There a Meaningful Clinical Difference?

Wilkinson ST, Rhee TG

Lamotrigine is not associated with differential clinical outcomes in a real-world sample of patients with unipolar depression receiving ketamine or esketamine.

Santucci MC, Katz RB, Pittman B +2

Ketamine for Depression, but at What Cost? A Review of Ketamine's Neurotoxic Effects From Preclinical and Human Studies.

Li SW, Kumpf KT, Urrutia J +3

Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study.

Zaki N, Chen LN, Lane R +10

Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.

Santucci MC, Ansari M, Nikayin S +3

Europe PMC2024

Blood pressure changes during ketamine infusion for the treatment of depression.

Ansari M, Pittman B, Tylee DS +3

Europe PMC2024

The Rapidly Shifting Ketamine Landscape in the US.

Wilkinson ST, Palamar JJ, Sanacora G

Europe PMC2024

Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.

Krystal JH, Kaye AP, Jefferson S +4

ArticlePsilocybin

Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.

Rhee TG, Davoudian PA, Sanacora G +1

Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol.

Kitay BM, Murphy E, Macaluso M +10

Trends in Illicit Ketamine Seizures in the US From 2017 to 2022.

Palamar JJ, Wilkinson ST, Carr TH +2